Allarity Therapeutics Inc Net Assets
Allarity Therapeutics Inc net assets. Based on the latest financial reports, Allarity Therapeutics Inc (ALLR) has net assets worth $9.83 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.26 Million) and total liabilities ($8.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ALLR shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.83 Million |
| % of Total Assets | 53.83% |
| Annual Growth Rate | 40.41% |
| 5-Year Change | -47.68% |
| 10-Year Change | 89.0% |
| Growth Volatility | 2562.37 |
Net Assets of Allarity Therapeutics Inc (2013–2025)
Net assets of Allarity Therapeutics Inc from 2013 to 2025. This chart illustrates how Allarity Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See ALLR net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Allarity Therapeutics Inc (2013–2025)
The table below shows the annual net assets of Allarity Therapeutics Inc from 2013 to 2025. For live market cap and overall valuation, see how much is Allarity Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $9.83 Million | -16.79% |
| 2024-12-31 | $11.81 Million | +529.33% |
| 2023-12-31 | $-2.75 Million | -245.56% |
| 2022-12-31 | $1.89 Million | -89.94% |
| 2021-12-31 | $18.78 Million | -30.04% |
| 2020-12-31 | $26.85 Million | +28.46% |
| 2019-12-31 | $20.90 Million | -25.09% |
| 2018-12-31 | $27.90 Million | +6981.67% |
| 2017-12-31 | $394.04K | -92.42% |
| 2016-12-31 | $5.20 Million | +5.43% |
| 2015-12-31 | $4.93 Million | +6153.65% |
| 2014-12-31 | $78.87K | -52.90% |
| 2013-12-31 | $167.44K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Allarity Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13014844744.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Allarity Therapeutics Inc Net Assets Breakdown (December 2025)
Allarity Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.03% |
| Other Comprehensive Income | $-1.02 Million | -10.39% |
| Other Components | $141.04 Million | 1435.11% |
| Total Equity | $9.83 Million | 100.00% |
Allarity Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Allarity Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rocketdna Ltd
AU:RKT
|
$17.48 Million |
|
Bright Scholar Education Holdings Ltd Class A
NYSE:BEDU
|
$17.48 Million |
|
Scidev Ltd
AU:SDV
|
$17.48 Million |
|
RPCG Public Company Limited
BK:RPC
|
$17.49 Million |
|
Southern Fertilizer JSC
VN:SFG
|
$17.47 Million |
|
Hands Corporation Ltd
KO:143210
|
$17.46 Million |
|
Chiangmai Frozen Foods Public Company Limited
BK:CM
|
$17.46 Million |
|
Kyntra Bio, Inc.
NASDAQ:KYNB
|
$17.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Allarity Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,811,000 to 9,828,000, a change of -1,983,000 (-16.8%).
- Net loss of 11,231,000 reduced equity.
- Share repurchases of 3,190,000 reduced equity.
- New share issuances of 13,838,000 increased equity.
- Other comprehensive income decreased equity by 667,000.
- Other factors decreased equity by 733,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.23 Million | -114.28% |
| Share Repurchases | $3.19 Million | -32.46% |
| Share Issuances | $13.84 Million | +140.8% |
| Other Comprehensive Income | $-667.00K | -6.79% |
| Other Changes | $-733.00K | -7.46% |
| Total Change | $- | -16.79% |
Book Value vs Market Value Analysis
This analysis compares Allarity Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.65x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.00x to 1.65x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $43044.22 | $1.13 | x |
| 2014-12-31 | $20274.04 | $1.13 | x |
| 2015-12-31 | $1267867.10 | $1.13 | x |
| 2016-12-31 | $1336772.49 | $1.13 | x |
| 2017-12-31 | $101296.40 | $1.13 | x |
| 2018-12-31 | $7173475.84 | $1.13 | x |
| 2019-12-31 | $5373521.85 | $1.13 | x |
| 2020-12-31 | $6902570.69 | $1.13 | x |
| 2021-12-31 | $2481373.84 | $1.13 | x |
| 2022-12-31 | $166666.67 | $1.13 | x |
| 2023-12-31 | $-812.70 | $1.13 | x |
| 2024-12-31 | $7.35 | $1.13 | x |
| 2025-12-31 | $0.68 | $1.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Allarity Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -114.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3509.69%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.86x
- Recent ROE (-114.28%) is above the historical average (-222.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -48.49% | 0.00% | 0.00x | 1.07x | $-97.93K |
| 2014 | -87.06% | -688.39% | 0.11x | 1.18x | $-76.55K |
| 2015 | -23.26% | -316.59% | 0.07x | 1.11x | $-1.64 Million |
| 2016 | -70.82% | -2570.36% | 0.02x | 1.26x | $-4.20 Million |
| 2017 | -1242.95% | -335.69% | 0.70x | 5.31x | $-4.94 Million |
| 2018 | -8.21% | -156.97% | 0.04x | 1.38x | $-5.08 Million |
| 2019 | -68.47% | -11927.50% | 0.00x | 1.51x | $-16.40 Million |
| 2020 | -24.59% | 0.00% | 0.00x | 1.24x | $-9.29 Million |
| 2021 | -141.87% | 0.00% | 0.00x | 2.64x | $-28.53 Million |
| 2022 | -849.63% | 0.00% | 0.00x | 7.70x | $-16.25 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.63 Million |
| 2024 | -207.56% | 0.00% | 0.00x | 1.92x | $-25.70 Million |
| 2025 | -114.28% | -3509.69% | 0.02x | 1.86x | $-12.21 Million |
Industry Comparison
This section compares Allarity Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Allarity Therapeutics Inc (ALLR) | $9.83 Million | -48.49% | 0.86x | $17.47 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Allarity Therapeutics Inc
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead d… Read more